Glucose-6-phosphate dehydrogenase deficiency future or investigational therapies
|
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
|
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glucose-6-phosphate dehydrogenase deficiency future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency future or investigational therapies |
|
FDA on Glucose-6-phosphate dehydrogenase deficiency future or investigational therapies |
|
CDC on Glucose-6-phosphate dehydrogenase deficiency future or investigational therapies |
|
Glucose-6-phosphate dehydrogenase deficiency future or investigational therapies in the news |
|
Blogs on Glucose-6-phosphate dehydrogenase deficiency future or investigational therapies |
|
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive hereditary disease featuring abnormally low levels of the G6PD enzyme, which plays an important role in red blood cell function. Individuals with the disease may exhibit non-immune hemolytic anemia in response to a number of causes. It is closely linked to favism, a disorder characterized by a hemolytic reaction to consumption of broad beans, with a name derived from the Italian name of the broad bean (fava). Sometimes the name, favism, is alternatively used to refer to the enzyme deficiency as a whole.